University of Richmond

UR Scholarship Repository
Biology Faculty Publications

Biology

2-2016

Effects of a Pyrrole-Based, MicrotubuleDepolymerizing Compound on RAW 264.7
Macrophages
John A. Ciemnieckia
Clarke P. Lewis
John T. Gupton
University of Richmond, jgupton@richmond.edu

Krista J. Stenger
University of Richmond, kstenger@richmond.edu

Follow this and additional works at: http://scholarship.richmond.edu/biology-faculty-publications
Part of the Biology Commons, and the Chemistry Commons
This is a pre-publication author manuscript of the final, published article.
Recommended Citation
John A. Ciemniecki, Clarke P. Lewis, John T. Gupton, and Krista Fischer-Stenger. "Effects of a Pyrrole-Based, MicrotubuleDepolymerizing Compound on RAW 264.7 Macrophages." In Chemico-Biological Interactions 246 (2016), 63-68. doi:10.1016/
j.cbi.2016.01.009.

This Post-print Article is brought to you for free and open access by the Biology at UR Scholarship Repository. It has been accepted for inclusion in
Biology Faculty Publications by an authorized administrator of UR Scholarship Repository. For more information, please contact
scholarshiprepository@richmond.edu.

Effects of a Pyrrole-Based, Microtubule-Depolymerizing Compound
on RAW 264.7 Macrophages

John A. Ciemnieckia, Clarke P. Lewisa, John T. Guptonb, Krista Fischer-Stenger*a
a

Department of Biology, University of Richmond, Richmond, VA 23173, United States

b

Department of Chemistry, University of Richmond, Richmond, VA 23173, United States

Final copy published in Chemico-Biological Interactions, 246 (2016), 63-68.

Abstract
RAW 264.7 murine macrophages were exposed to the pyrrole-based compound 3,5Dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester (JG-03-14), which
is a known microtubule depolymerizing agent with antitumor activity. 1,2,3,4 In this study
exposure to JG-03-14 reduced the production of pro-inflammatory molecules by macrophages
activated with lipopolysaccharide (LPS). Treatment with the pyrrole-based compound decreased
the concentration of tumor necrosis factor-α (TNF-α) and nitric oxide (NO) released from the
macrophages. Exposure to JG-03-14 also decreased TNF-α mRNA expression levels and the
protein expression levels of inducible nitric oxide synthase (iNOS), the enzyme responsible for
NO production in the activated macrophages. Furthermore, JG-03-14 treatment significantly
changed the degradation profile of IκB-β, an inhibitor of the NF-κB transcription factor, which
suggests that JG-03-14 may attenuate the activation of the LPS-induced NF-κB signaling
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pathway needed to produce the pro-inflammatory mediators. We conclude that JG-03-14
possesses anti-inflammatory properties.

Keywords:
JG-03-14 pyrrole compound, RAW264.7 macrophages, inflammation, NF-κB, TNF-α, nitric
oxide

1. Introduction
Studies of 3,5-Dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl
ester (JG-03-14, Figure 1), a tetrasubstituted brominated pyrrole, have demonstrated that this
compound possesses potent microtubule depolymerizing properties by binding tubulin at the
colchicine site.1,2,3 As a major component of the eukaryotic cytoskeleton, microtubules
contribute to cell physiology by participating in chromosome segregation during mitosis,
organelle trafficking and cell signaling events, and disruption of tubulin dynamics is the target of
several anticancer drugs. Although colchicine was the first drug shown to bind tubulin, resulting
in the loss of microtubules and the prevention of new microtubule formation, it is too toxic to be
used in a clinical setting.4,5,6 Therefore, less toxic compounds, such as JG-03-14, that bind at the
colchicine site of tubulin have drawn considerable attention. Earlier studies that demonstrated the
importance of the C-2 and C-4 positions of JG-03-14 for tubulin binding also showed that the
tubulin-depolymerizing property of this compound correlated with anti-proliferative activity in a
wide range of cancer cell lines.2,3 Further investigations demonstrated that JG-03-14 promotes
autophagic cell death of tumor cells and that it is active against tumor cells expressing the
multidrug resistance pump, providing additional support for the potential use of JG-03-14 to treat
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malignancies.7,8 However, little is known about the effect of JG-03-14 on immune cells,
specifically macrophages, which detect invading microorganisms in the tissues, carry out
phagocytosis, and produce pro-inflammatory mediators.9 While acute inflammation is protective
against infections and tissue injury, chronic inflammation may lead to inflammatory disorders
and cancers.10,11,12,13,14 Studies have shown that other pyrrole-containing compounds possess
anti-inflammatory properties.15,16,17 Therefore, in addition to understanding the microtubule
depolymerizing properties of JG-03-14, investigating the effects of JG-03-14 on the proinflammatory activity of macrophages is important in order to expand our knowledge of the
compound’s bioactive properties and its clinical potential.

(JG-03-14)
Figure 1. Structure of 3,5-Dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid ethyl ester (JG-03-14).

The Nuclear Factor-kappa B (NF-κB) transcription factor is one of the most important
regulators of the inflammatory response. In macrophages, the pro-inflammatory NF-κB signaling
pathway can be activated by lipopolysaccharide (LPS), a cell wall component of gram-negative
bacteria, which binds to the Toll-like receptor 4 (TLR4) complex and triggers the production of
pro-inflammatory molecules.9 Initiation of this pathway involves a complex signaling
architecture that ultimately phosphorylates and activates the IKK complex, which in turn
phosphorylates the inhibitory proteins IκB-α and IκB-β that are bound to the NF-κB transcription
factor.18 These inhibitory proteins are then ubiquitinated and degraded in a cytosolic
proteasome.18 The now-active NF-κB translocates into the nucleus and promotes the
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transcription of inflammatory response genes. In mice, some of these genes include TNFA, which
encodes the cytokine tumor necrosis factor-α (TNF-α) and NOS2, which encodes inducible nitric
oxide synthase (iNOS). The iNOS enzyme catalyzes the reaction of L-arginine to citrulline,
which produces nitric oxide (NO) radicals as a byproduct, useful as both a vasodilator and an
anti-pathogenic oxidant.
To assess the effects of JG-03-14 on the macrophage inflammatory response, our study
investigated how exposure to JG-03-14 affected the production of NO, iNOS, and TNF-α by
RAW 264.7 macrophages activated with LPS. We also investigated JG-03-14's effects on the
relative mRNA expression of TNF-α as well as the degradation of the IκB-β inhibitory protein
after LPS activation. We found that JG-03-14 suppressed the production of the inflammatory
molecules and our data further suggest that this may be caused by an effect on the NF-κB
signaling pathway.

2. Materials and methods
2.1 Cell Culture
RAW 264.7 macrophages were purchased from ATCC and plated in T75 filter-top flasks,
where they were managed under sterile conditions and grown at 37°C with 5% CO2. Cells were
maintained in RPMI complete medium containing 10% fetal calf serum and supplemented with
L-glutamine, non-essential amino acids, MEM vitamins, and penicillin/streptomycin and grown
to approximately 75-95% confluence. Cell populations were activated with LPS (E. coli 055:B5;
Sigma-Aldrich). Cell lysates and supernatants were harvested 2.5 minutes to 2 hours after LPSactivation for IκB-β experiments, 4 hours after activation for TNF-α experiments, and 20 hours
after activation for NO/iNOS studies. The JG-03-14 compound was provided by Dr. John
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Gupton and solubilized in DMSO, and then diluted in fresh medium (to < 1% DMSO) before
being added to culture media. In all experiments, JG-03-14 compound was administered 1 hour
before LPS activation. After LPS incubation, cell culture supernatants were collected. Adherent
cells were then washed twice with phosphate buffered saline (PBS), and homogenized with lysis
buffer consisting of 0.05 M Tris buffer (pH 7.5), 0.3 M NaCl, 2 mM EDTA, 0.5% Triton-X 100,
2 μg/mL Leupeptin (Sigma-Aldrich), 1 μg/mL Aprotinin (Sigma-Aldrich), and 0.2 mM PMSF
(Sigma-Aldrich). Both supernatants and lysates were stored at -20°C until assayed.

2.2 Fluorescence Microscopy
Cells were plated on coverslips held in 6-well plates and allowed to adhere overnight. After
exposure to JG-03-14 and a 4-hour LPS activation period, cells were washed with PBS, fixed
with paraformaldehyde for 10 minutes, washed with 0.5% Triton-X in PBS for 5 minutes, and
then placed in a donkey serum blocking solution for 30 minutes. Cells were then incubated in 1
ug/mL mouse anti-α-tubulin antibody by placing coverslips facedown on a parafilm surface in
the antibody diluted in the block solution for 30 minutes. The coverslips were then washed in
PBS for 5 minutes four times. Cells were then incubated in 1:4000 dilution of DAPI, 1:1000
dilution of phalloidin, and 1:10,000 dilution of donkey anti-mouse antibody conjugated to
ALEXA 488 for 30 minutes. The coverslips were again washed in PBS for 5 minutes four times.
Coverslips were then mounted onto microscope slides in glycerol mounting media and sealed
with clear nail polish. Images were acquired using an Olympus IX-83 microscope outfitted with
a PLAN APON 60x/1.42NA DIC objective, an EXFO mixed gas light source, Sutter filter
wheels and shutters, a Hamamatsu ORCA-Flash 4.0 V2 sCMOS camera, and Metamorph
imaging software. Z-stack images (0.2 μm steps) were captured sequentially using the Sedat
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Quad filter-set (Chroma), and exposure times were maintained constant within an experimental
data set.

2.3 MTT Cell Viability Assay
MTT compound (Sigma-Aldrich) was solubilized in PBS in limited light conditions at a
concentration of 5 mg/mL and left overnight at 4°C to dissolve completely. Populations of 5.0 x
103 cells were added to wells in a 96-well flat-bottom microtiter plate and were allowed to
adhere for 2 hours before media was aspirated and replaced with 100 mL fresh media. Cells were
then administered JG-03-14 and underwent a 20-hour incubation. Next 10 uL of the MTT
solution were added to each well in limited light conditions and allowed to incubate in the dark
for 4 hours in the CO2 incubator. The formazan crystals were solubilized with 100 uL of
isopropanol in 0.04 M HCl. Absorbance was immediately read at 570 nm using a BeckmanCoulter DTX 800 Multimode Detector. It is also important to note that for all experiments
performed in this study microscopic examination did not detect any noticeable differences in the
viability of cultures, regardless of treatment (data not shown).

2.4 Nitric Oxide Assay
Populations of 3.3 x 106 cells were incubated with LPS for 20 hours before being harvested
for NO assessment. Nitrite accumulation in the supernatants was assessed using a standard
Greiss assay. Briefly, an equal volume of supernatant (50 μL) was reacted with equal volumes of
each Greiss reagent (50 μL each) and the absorbance was read at 550 nm using a BeckmanCoulter DTX 800 Multimode Detector.
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2.5 Western Blotting
Populations of 3.3 x 106 (for iNOS) and 5.0 x 105 cells (for IκB-β) were treated as previously
described. Thirty μg of protein from each cell lysate was separated on a 10% gel (Bio-Rad MiniPROTEAN TGX Stain-Free Pre-Cast Gels) and transferred to a nitrocellulose membrane (BioRad). Membranes were blocked for 1 hour with 5% non-fat dry milk solubilized in Tris-buffered
saline (TBS), followed by a 5 minute TBS wash. To detect the protein of interest, the membranes
were incubated overnight at 4°C with the primary antibody (Santa-Cruz Biotechnologies) diluted
1:200 in TBST (TBS with 0.2% non-fat dry milk and 0.1% Tween-20). The membrane was then
washed three times for 10 minutes in TBST and incubated with the appropriate secondary
antibody (Santa-Cruz Biotechnologies) diluted 1:7500 in TBST for 1 hour at room temperature
with gentle agitation. The membrane was then washed four times for 5 minutes each in TBST
and visualized using GE Healthcare Amersham ECL Western Blotting detection reagents and
Kodak Biomax XAR Film. Blots were stripped with Millipore Re-Blot Plus Mild Antibody
Stripping Solution according to the manufacturer’s instructions and re-probed using a mouse
anti-actin antibody (Sigma-Aldrich) at a 1:5000 dilution using the previously described
procedure.

2.6 TNF-α ELISA
Populations of 3.3 x 106 cells were treated as previously described. Supernatant samples
collected from the cultures were diluted 1:100 then analyzed to quantify the presence of TNF-α
using an OptEIATM ELISA assay (BD Biosciences). Protocol was carried out according to the
manufacturer’s directions.
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2.7 TNF-α qPCR
Populations of 3 x 105 cells were treated as previously described. RNA from these cultures
was harvested using the Qiagen RNEasy Mini-Kit. After RNA was collected, cDNA was created
using Origene's First-Strand cDNA Synthesis Kit following Origene's standard protocols and
using a Bio-Rad DNAEngine thermo-cycler. The gene of interest was amplified using Origene
primers (qSTAR qPCR primer pairs against Mus musculus Tnf and Actb) and Quanta
Biosciences B-R SYBR Green SuperMix for iQ in 20 μL reactions. Reaction progress was
monitored using a Bio-Rad CFX Connect Real-Time System and its associated software. Cq data
were analyzed using a normalized expression method (ΔΔCq).

2.8 IκB-β Densitometry and Analysis
Densitometry of IκB-β western blots was completed using a Kodak Gel Logic 200 imaging
system and its associated software. Densities were normalized against the initial density of IκB-β
on each blot. The relative density values were then linearized assuming exponential decay by
taking the natural logarithm of the relative densities. The best-fit linear slope was then averaged
between independent experimental replicates for comparison. Standard error was calculated from
the variability of this slope between replicates but not the variability from the fit of the individual
data sets to a linear trend. The minimum relative densities were also averaged between
independent experimental replicates for comparison, and once again standard error was
calculated from the variability of these relative density minima.

2.9 Statistics
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All data were analyzed using Graphpad PRISM software and a one-way ANOVA test, except
for IκB-β densitometry data, which utilized heteroscedastic two-tailed t-tests for comparison of
the means.

3. Results
3.1 Microtubule network
The microtubule-depolymerizing effects of JG-03-14 were confirmed using fluorescence
microscopy of RAW 264.7 cells treated with JG-03-14 with and without subsequent LPS
activation (Figure 2). Qualitative assessment showed that resident macrophages demonstrated
consistent, diffuse distribution of microtubules, while activation of these macrophages with LPS
increased microtubule organizing center (MTOC) brightness and microtubule network
complexity. This is consistent with previous studies.19,20 When pretreated with JG-03-14, the
cells failed to construct a diffuse microtubule network as seen in the resident macrophages,
however, LPS activation still increased MTOC brightness despite the lack of a clear microtubule
network.
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Microtubules
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0.5 μM JG-03-14

0.5 μM JG-03-14
+
500 ng/mL LPS
Figure 2. Effect of JG-03-14 on microtubule polymerization and distribution in RAW 264.7 cells. Cells were treated with JG-03-14 one
hour before a 4 hour LPS activation, fixed with paraformaldehyde, and stained with anti-α-tubulin antibody (Alexa 488), DAPI, and
Phalloidin (Alexa 568). Images are shown on the same brightness scale as a z-stack composite and were taken with the same exposure time.
Overlay shows f-actin (Phalloidin) in magenta, microtubules (Alexa 488) in cyan, and nuclei (DAPI) in yellow. White scale bar is 20 μm.

3.2 Cell viability
Next, RAW 264.7 cells in culture were assessed for viability across a range of JG-03-14
concentrations over a 21-hour incubation period. A slight decrease in cell viability was detected
after exposure to concentrations up to eight times those used in this study (Figure 3).
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Figure 3. Effect of JG-03-14 on RAW 264.7 Cell Viability. Populations of 5,000 cells were exposed to varying
concentrations of JG-03-14 for 20 hours. Viability was assessed using an MTT assay and is reported as a
percentage of the control sample. Representative figure of an experiment conducted in independent triplicate.

3.3 Production of pro-inflammatory molecules
In order to assess the effects of JG-03-14 on the inflammatory response, we analyzed NO
production by LPS-activated RAW 264.7 cells with and without JG-03-14 pretreatment using a
standard Greiss assay. We found that NO production was significantly reduced in cells pretreated
for one hour with 0.5 μM JG-03-14 and activated with 500 ng/mL LPS (Figure 4a).
Corresponding iNOS levels within the lysates from the same cells were also examined using
western blot analysis, and results correlated with NO levels (Figure 4b). We also measured TNFα released from the macrophages using an ELISA and found the amount of secreted TNF-α to be
significantly reduced in cells pretreated with either 0.25 or 0.5 μM JG-03-14 (Figure 5a). We
then used qPCR to compare the relative TNFA expression levels between activated macrophages
exposed to JG-03-14 and those that were not. Relative expression levels of TNFA mRNA were
found to be decreased in cultures pretreated with either 0.25 or 0.5 μM JG-03-14 (Figure 5b).
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Figure 4. Effect of JG-03-14 on NO and iNOS production in activated RAW 264.7 macrophages. Cells were pretreated with JG-03-14
one hour before LPS activation. Cells were incubated 20 hours after LPS activation. (A) Nitric oxide production in activated RAW
264.7 macrophages. (B) Western blot showing iNOS production in the same sample of RAW 264.7 macrophages. Both are
representative of an experiment conducted in independent triplicate. *p<0.05.

A

B

Figure 5. Effect of JG-03-14 on TNF-α and TNFA mRNA production in activated RAW 264.7 macrophages. Cells were pretreated with JG03-14 1 hour before LPS activation, then incubated 4 hours. (A) Concentration of TNF-α secreted protein as measured by ELISA (B) Relative
expression of TNFA mRNA as measured by qPCR. Representative figures of experiments conducted in independent triplicate. Means
compared to LPS control using one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001.
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3.4 NF-κB activation
We hypothesized that the attenuation of iNOS and TNF-α protein expression may be due
to an effect that JG-03-14 has on the activation of the NF-κB transcription factor. To assess the
effect of the compound on the NF-κB activation in RAW 264.7 macrophages, we tracked the
relative amounts of IκB-β over time within the macrophages using western blot analysis. Our
results show that pretreatment with JG-03-14 significantly altered the degradation profile of IκBβ within activated RAW 264.7 macrophages (Figure 6a and 6b). Densitometry of the bands
representing IκB-β protein relative to the band at t = 0 was used to quantify and analyze the
effect of JG-03-14 on the degradation of IκB-β (Figure 6c). In order to assess differences in the
IκB-β degradation rate between the cells pretreated with 0.5 μM JG-03-14 and those that were
not, the densitometry data were linearized assuming exponential decay and a best-fit linear slope
was found for each of the resultant data. The magnitude of the slope was found to be
significantly decreased when analyzed from cells pretreated with 0.5 μM JG-03-14 (figure 7a),
indicating that the rate of decay of the steady state amount of IκB-β within the cells after LPS
activation was also decreased. Furthermore, the minimum density band on each blot was found
and averaged between independent experiments. The minimum IκB-β level in the activated cells
during the first two hours after LPS activation was found to be increased by about 20% in cells
pretreated for one hour with 0.5 μM JG-03-14 (Figure 7b), indicating that the minimum steadystate amount of IκB-β in the cells was significantly greater in the cells pretreated with JG-03-14.
These results, taken together with the observed decrease in production of inflammatory
molecules by activated macrophages, suggest that exposure to JG-03-14 may be suppressing NFκB's ability to promote pro-inflammatory gene transcription in response to LPS stimulation.
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A

(+) 100 ng/mL LPS
(+) 100 ng/mL LPS
(+) 0.5 μM JG-03-14
(-) JG-03-14
____________________________ ___________________________
0' 2.5' 5'

10' 20' 40' 1h 2h 0' 2.5' 5' 10' 20' 40' 1h 2h
45 kDa

IκB-β
Relative Density

1.00 1.14

0.79

0.74

0.64

0.34 0.31 0.24 1.00 1.02 1.08

β-Actin

0.93 0.90

0.51

0.48

0.58

42 kDa

Figure 6. Effect of JG-03-14 on steady-state amount of IκB-β over time. (A) Cells were activated with LPS and lysed at indicated time points
and analyzed by western blotting. (B) Cells were treated with JG-03-14 for 1 hour, then activated with LPS and lysed at indicated time points.
(C) Relative densitometry representation of (A) and (B). Band densities normalized to the initial IκB-β band (0’ time point) on the respective blot.
Representative figures of experiments conducted in independent triplicate.

A

B

Figure 7. Analysis of IκB-β densitometry. (A) Densitometry data were linearized assuming an exponential decay trend (D = e-kt, where D is the
relative densitometry value, t is the time in minutes, and k is the rate of decay), and the best-fit linear slopes for each treatment were compared.
(B) Minimum IκB-β band densities relative to the t = 0 band density in the corresponding data set for each treatment were compared. In each
comparison, means were calculated from data collected from three independent experiments, and compared using a heteroscedastic two-tailed ttest. **p<0.01, ***p<0.001.

4. Discussion
Previous studies have shown that JG-03-14 possesses potent microtubule depolymerizing and
anti-tumor activity, lending support to the compound's potential as a cancer chemotherapeutic
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agent.1,7,8 We have shown that JG-03-14 disrupts microtubule polymerization and distribution
within RAW 264.7 cells, and in activated macrophages it decreases the production of iNOS and
NO radicals as well as TNF-α mRNA and protein. JG-03-14 also delays and decreases the
degradation of the IκB-β protein, one of the inhibitory proteins whose degradation is coupled
with the activation of the NF-κB transcription factor that is responsible for the induction of proinflammatory genes. Our data, therefore, indicate that JG-03-14 also possesses anti-inflammatory
properties, adding support to other studies demonstrating the anti-inflammatory properties of
pyrrole compounds.15,16,17
The change in the IκB-β degradation profile due to pretreatment with JG-03-14 could
have multiple independent or inter-related causes. The study we conducted showed the change in
the steady-state amount of IκB-β over time after macrophage activation, which can be affected
both by the kinetics of IκB-β degradation and resynthesis of the protein. It is also known that
newly synthesized IκB-β in a hypophosphorylated form can bind to NF-κB in the nucleus
without inhibiting NF-κB's ability to bind to DNA and promote gene transcription.21 Our
technique did not discriminate between IκB-β with and without post-translational modifications.
Therefore, there are several ways that JG-03-14 may be mediating the observed antiinflammatory effect. While it is possible that the destabilization of microtubules by JG-03-14
could be disrupting vesicle trafficking resulting in a reduction in TNF-α secreted by the
macrophages, our results also suggest that this compound may directly affect the components of
the LPS-induced NF-κB pathway, or possibly alter the events leading to the degradation of IκBβ. Another intriguing possibility is that JG-03-14's effect on NF-κB activation is a consequence
of its anti-microtubule activity, which would suggest a connection between the microtubule
network and the LPS-induced NF-κB pathway. Recent studies showing a connection between
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cytoskeletal proteins and the activation and/or kinetics of the NF-κB pathway make this
possibility an important foundation for future inquiry.22 Furthermore, a study published in 1992
reported that the compound taxol, a potent microtubule stabilizer, exerted LPS-like effects upon
macrophages by inducing the mRNA expression of TNF-α and interleukin-1β in the absence of
LPS.23 The fact that a microtubule stabilizer induced the expression of pro-inflammatory
products in that study and a microtubule destabilizer repressed pro-inflammatory products in the
present one may be a coincidence, but it warrants further investigation. These future studies may
reveal a novel interaction between microtubules and the signaling components responsible for
the activation of NF-κB.
If JG-03-14 is instead found to have a direct interaction with the signaling components of
the NF-κB pathway, it may increase its potential as an anti-tumor agent. Indeed, many cancers
are exacerbated by a constitutively active NF-κB transcription factor, which can be caused by
various perturbations or mutations in the normal pathway and its signaling termination
programs.13,24 A compound that has anti-tumor properties while also debasing a cancer cell's
resistance to chemotherapeutics may have clinical attractiveness for treating more aggressive
cancers. Besides elucidating the targets of JG-03-14, it would also be prudent to test JG-03-14's
anti-tumor efficacy on aggressive cancer types known to contain aberrations in their NF-κB
signaling machinery.
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